7月28日，吉利德科学盘中上涨3.13%，报135.76美元/股，成交额2.47亿美元。当日生物科技板块整体走强，安进涨5.67%、因塞特医疗涨4.67%、艾伯维涨3.66%，板块联动效应明显。
消息面上，公司将于8月4日盘后发布季度财报，市场预计营收同比增长6.13%，机构观点偏多。同时，欧洲药品管理局CHMP于7月24日推荐批准Trodelvy联合Keytruda用于PD-L1阳性一线转移性三阴性乳腺癌，若获欧盟委员会正式批准，Trodelvy将实现mTNBC一线治疗全覆盖布局，进一步打开肿瘤管线商业化空间。此前该药已获FDA批准一线适应症，产品放量预期持续强化。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.